Tirzepatide treatment begins with a starting dose of 2.5 mg, and it is administered subcutaneously once weekly
Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery kidney problems (kidney failure)
That dual approval reflects the compound mechanism of action, which treats weight and metabolic health as interconnected problems rather than separate issues
Adequate hydration is essential, as dehydration from nausea, vomiting, or diarrhea can cause dry eyes and temporary visual disturbances
The FDA prescribing information for tirzepatide includes warnings about acute pancreatitis, gallbladder disease, and acute kidney injury risk with dehydration
Seek urgent medical attention (contact your GP immediately, call NHS 111, or attend A&E/call 999 if severe) if you develop severe abdominal pain, persistent vomiting preventing fluid intake, signs of dehydration, or significantly elevated blood glucose levels
:format(webp))
